Form preview

Get the free CHEMISTRY REVIEW NDA 22-272 OxyContin - accessdata fda

Get Form
This document provides a comprehensive review of the chemistry, manufacturing, and controls (CMC) related to the New Drug Application (NDA) for OxyContin tablets, addressing the formulation, stability
We are not affiliated with any brand or entity on this form

Get, Create, Make and Sign chemistry review nda 22-272

Edit
Edit your chemistry review nda 22-272 form online
Type text, complete fillable fields, insert images, highlight or blackout data for discretion, add comments, and more.
Add
Add your legally-binding signature
Draw or type your signature, upload a signature image, or capture it with your digital camera.
Share
Share your form instantly
Email, fax, or share your chemistry review nda 22-272 form via URL. You can also download, print, or export forms to your preferred cloud storage service.

How to edit chemistry review nda 22-272 online

9.5
Ease of Setup
pdfFiller User Ratings on G2
9.0
Ease of Use
pdfFiller User Ratings on G2
Use the instructions below to start using our professional PDF editor:
1
Log in. Click Start Free Trial and create a profile if necessary.
2
Prepare a file. Use the Add New button to start a new project. Then, using your device, upload your file to the system by importing it from internal mail, the cloud, or adding its URL.
3
Edit chemistry review nda 22-272. Add and change text, add new objects, move pages, add watermarks and page numbers, and more. Then click Done when you're done editing and go to the Documents tab to merge or split the file. If you want to lock or unlock the file, click the lock or unlock button.
4
Get your file. When you find your file in the docs list, click on its name and choose how you want to save it. To get the PDF, you can save it, send an email with it, or move it to the cloud.
Dealing with documents is simple using pdfFiller.

Uncompromising security for your PDF editing and eSignature needs

Your private information is safe with pdfFiller. We employ end-to-end encryption, secure cloud storage, and advanced access control to protect your documents and maintain regulatory compliance.
GDPR
AICPA SOC 2
PCI
HIPAA
CCPA
FDA

How to fill out chemistry review nda 22-272

Illustration

How to fill out CHEMISTRY REVIEW NDA 22-272 OxyContin

01
Gather all necessary documents and information for the Chemistry Review.
02
Start by filling out your personal information, including name, address, and contact details.
03
Provide detailed information about the OxyContin formulation, including ingredient composition and concentration.
04
Describe the manufacturing process of OxyContin step by step.
05
Include data from any stability studies or clinical trials related to OxyContin.
06
Ensure that all required signatures and dates are included at the end of the form.
07
Review the completed form carefully for accuracy before submission.
08
Submit the filled form to the appropriate regulatory agency.

Who needs CHEMISTRY REVIEW NDA 22-272 OxyContin?

01
Pharmaceutical companies developing or producing OxyContin.
02
Regulatory agencies reviewing applications for new drug formulations.
03
Researchers studying the pharmacology or chemistry of OxyContin.
04
Healthcare professionals seeking to understand the formulation for prescribing purposes.
Fill form : Try Risk Free
Users Most Likely To Recommend - Summer 2025
Grid Leader in Small-Business - Summer 2025
High Performer - Summer 2025
Regional Leader - Summer 2025
Easiest To Do Business With - Summer 2025
Best Meets Requirements- Summer 2025
Rate the form
4.0
Satisfied
22 Votes

People Also Ask about

The original formulations of the drug, including OxyContin and its generic, “poses an increased potential for abuse by certain routes of administration,” says Morgan Liscinsky, a spokesperson for the FDA. “The agency has therefore determined that the benefits of original OxyContin no longer outweigh its risks.”
Adult dosing Acute pain: Initial recommended doses of oxycodone are in the 5 mg to 15 mg range, every 4 to 6 hours as needed for adequate analgesia of acute pain. Further dosing should be titrated upwards for pain control, with attention and monitoring for adverse effects.
A single dose greater than 40 mg, or total daily doses greater than 80 mg, may cause fatal respiratory depression when administered to patients who are not tolerant to the respiratory depressant effects of opioids.
OxyContin® tablets 5 mg, 10 mg, 20 mg, 40 mg and 80 mg are dose-proportional in terms of both rate and extent of absorption. OxyContin® tablets 15 mg and 30 mg are bioequivalent to OxyContin® tablets 40 mg in terms of AUCt, AUCinf and Cmax of oxycodone, and mean half-life values and median tmax were all similar.
Increasing severity of pain will require an increased dosage of OxyContin® tablets using the 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg, 120 mg & 160 mg tablet strengths, either alone or in combination, to achieve pain relief.
Dosage and strength Oxycodone comes as: capsules containing 5mg, 10mg or 20mg of oxycodone – usually taken 4 to 6 times a day. standard tablets containing 5mg, 10mg or 20mg of oxycodone – usually taken 4 to 6 times a day.
OxyContin 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg1 and 80 mg tablets have been reformulated, and comprise a matrix formulation with a hydrogelling property (i.e. particles or whole tablets become highly viscous (gel-like) in water), intended to be crush-deterrent and to reduce the rapid release of oxycodone upon

For pdfFiller’s FAQs

Below is a list of the most common customer questions. If you can’t find an answer to your question, please don’t hesitate to reach out to us.

CHEMISTRY REVIEW NDA 22-272 OxyContin is a regulatory submission to the FDA for the approval of OxyContin, a prescription opioid medication used for the management of pain.
The pharmaceutical company developing OxyContin or responsible for its manufacture is required to file CHEMISTRY REVIEW NDA 22-272.
To fill out CHEMISTRY REVIEW NDA 22-272 OxyContin, the applicant must complete the necessary forms, provide detailed chemical and manufacturing information, and comply with FDA guidelines for submission.
The purpose of CHEMISTRY REVIEW NDA 22-272 OxyContin is to evaluate the safety, efficacy, and quality of the OxyContin formulation before it can be marketed.
The information that must be reported includes the chemical composition, manufacturing process, quality control measures, stability data, and proposed labeling for OxyContin.
Fill out your chemistry review nda 22-272 online with pdfFiller!

pdfFiller is an end-to-end solution for managing, creating, and editing documents and forms in the cloud. Save time and hassle by preparing your tax forms online.

Get started now
Form preview
If you believe that this page should be taken down, please follow our DMCA take down process here .
This form may include fields for payment information. Data entered in these fields is not covered by PCI DSS compliance.